Expression of microRNA-146 suppresses NF-κB activity with reduction of metastatic potential in breast cancer cells von Bhaumik, D, Scott, G K, Schokrpur, S, Patil, C K, Campisi, J, Benz, C C

Volltext

Rapid alteration of MicroRNA levels by histone deacetylase inhibition von SCOTT, Gary K, MATTIE, Michael D, BERGER, Crystal E, BENZ, Stephen C, BENZ, Christopher C

Volltext

Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial von Johansson, Annelie, Dar, Huma, van 't Veer, Laura J, Tobin, Nicholas P, Perez-Tenorio, Gizeh, Nordenskjöld, Anna, Johansson, Ulla, Hartman, Johan, Skoog, Lambert, Yau, Christina, Benz, Christopher C, Esserman, Laura J, Stål, Olle, Nordenskjöld, Bo, Fornander, Tommy, Lindström, Linda S

Volltext

Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer von Lindström, Linda S, Yau, Christina, Czene, Kamila, Thompson, Carlie K, Hoadley, Katherine A, Van't Veer, Laura J, Balassanian, Ron, Bishop, John W, Carpenter, Philip M, Chen, Yunn-Yi, Datnow, Brian, Hasteh, Farnaz, Krings, Gregor, Lin, Fritz, Zhang, Yanhong, Nordenskjöld, Bo, Stål, Olle, Benz, Christopher C, Fornander, Tommy, Borowsky, Alexander D, Esserman, Laura J

Volltext

Clinical development of histone deacetylase inhibitors as anticancer agents von DRUMMOND, Daryl C, NOBLE, Charles O, KIRPOTIN, Dmitri B, ZEXIONG GUO, SCOTT, Gary K, BENZ, Christopher C

Volltext

Clinical and molecular characteristics of estrogen receptor‐positive ultralow risk breast cancer tumors identified by the 70‐gene signature von Johansson, Annelie, Yu, Nancy Y., Iftimi, Adina, Tobin, Nicholas P., 't Veer, Laura, Nordenskjöld, Bo, Benz, Christopher C., Fornander, Tommy, Perez‐Tenorio, Gizeh, Stål, Olle, Esserman, Laura J., Yau, Christina, Lindström, Linda S.

Volltext

Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades von Esserman, LJ, Yau, C, Thompson, CK, van't Veer, LJ, Borowsky, AD, Hoadley, KA, Tobin, NP, Nordenskjold, B, Fornander, T, Stal, O, Benz, CC, Lindstrom, LS

Volltext

Future directions of liposome- and immunoliposome-based cancer therapeutics von Park, John W., Benz, Christopher C., Martin, Francis J.

Volltext

Anti-HER2 immunoliposomes: Enhanced efficacy attributable to targeted delivery von PARK, John W, KEELUNG HONG, PAPAHADJOPOULOS, Demetrios, BENZ, Christopher C, KIRPOTIN, Dmitri B, COLBERN, Gail, SHALABY, Refaat, BASELGA, Jose, SHAO, Yvonne, NIELSEN, Ulrik B, MARKS, James D, MOORE, Dan

Volltext

Assessment of Long-term Distant Recurrence-Free Survival Associated With Tamoxifen Therapy in Postmenopausal Patients With Luminal A or Luminal B Breast Cancer von Yu, NY, Iftimi, A, Yau, C, Tobin, NP, van 't Veer, L, Hoadley, KA, Benz, CC, Nordenskjold, B, Fornander, T, Stal, O, Czene, K, Esserman, LJ, Lindstrom, LS

Volltext

The NFκB pathway and endocrine-resistant breast cancer von Zhou, Y, Eppenberger-Castori, S, Eppenberger, U, Benz, C C

Volltext

Tamoxifen therapy benefit for patients with 70-gene signature high and low risk von van ‘t Veer, Laura J., Yau, Christina, Yu, Nancy Y., Benz, Christopher C., Nordenskjöld, Bo, Fornander, Tommy, Stål, Olle, Esserman, Laura J., Lindström, Linda Sofie

Volltext

Abstract P6-06-21: A 5-gene predictor of triple negative breast cancer outcome that also correlates with immune checkpoint receptor expression von Yau, C, Campbell, M, Esserman, L, Benz, CC

Volltext

Characterization of Benign Breast Diseases and Association With Age, Hormonal Factors, and Family History of Breast Cancer Among Women in Sweden von Johansson, Annelie, Christakou, Athanasia E., Iftimi, Adina, Eriksson, Mikael, Tapia, Jose, Skoog, Lambert, Benz, Christopher C., Rodriguez-Wallberg, Kenny A., Hall, Per, Czene, Kamila, Lindstrom, Linda S.

Volltext

Tumor targeting using anti-her2 immunoliposomes von Park, J.W., Kirpotin, D.B., Hong, K., Shalaby, R., Shao, Y., Nielsen, U.B., Marks, J.D., Papahadjopoulos, D., Benz, C.C.

Volltext

Abstract PD2-04: ERα phosphorylation at pS294: A biomarker of ligand or mutational (Y537S, D538G) activation, and a receptor target for CDK2 inhibition von Benz, CC, Scott, GK, Chu, D, Kaur, R, Muthurajah, M, Rothschild, D, Frazier, K, Park, BH

Volltext

Increased long-term risk of fatal breast cancer in patients with high intra-tumor heterogeneity of the estrogen receptor – Retrospective analyses of the STO-3 trial von Lindström, L.S., Yau, C., Czene, K., Thompson, C., Yu, N., Nordenskjöld, B., Stål, O., Benz, C.C., Fornander, T., Borowsky, A.D., Esserman, L.

Volltext

Abstract PD7-02: Identification of breast cancers with an indolent disease course: 70 gene indolent threshold validation in a Swedish randomized trial of tamoxifen vs. not, with 20... von Esserman, LJ, Yau, C, Thompson, CK, van't Veer, LJ, Borowsky, AD, Hoadley, KA, Tobin, NP, Nordenskjöld, B, Fornander, T, Stål, O, Benz, CC, Lindström, LS

Volltext

Abstract P2-05-03: Intra-tumor heterogeneity of the estrogen receptor predicts less benefit from tamoxifen therapy and poor long-term breast cancer patient survival – Retrospective... von Lindström, LS, Yau, C, Czene, K, Thompson, CK, van't Veer, LJ, Nordenskjöld, B, Stål, O, Fornander, T, Benz, CC, Borowsky, AD, Esserman, LJ

Volltext

Activation of nuclear factor-κB (NFκB) identifies a high-risk subset of hormone-dependent breast cancers von Zhou, Yamei, Eppenberger-Castori, Serenella, Marx, Corina, Yau, Christina, Scott, Gary K., Eppenberger, Urs, Benz, Christopher C.

Volltext